Compare GRF & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRF | TELA |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.9M | 36.7M |
| IPO Year | N/A | 2019 |
| Metric | GRF | TELA |
|---|---|---|
| Price | $10.82 | $0.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.31 |
| AVG Volume (30 Days) | 3.0K | ★ 330.9K |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | ★ $77,055,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | N/A | $15.20 |
| P/E Ratio | $8.15 | ★ N/A |
| Revenue Growth | N/A | ★ 12.24 |
| 52 Week Low | $7.93 | $0.68 |
| 52 Week High | $10.19 | $2.96 |
| Indicator | GRF | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 36.78 |
| Support Level | $10.75 | $0.76 |
| Resistance Level | $11.09 | $0.86 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 45.60 | 27.30 |
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.